Orchid Pharma Allots 4.45 Cr Equity Shares Pursuant to Amalgamation Scheme
Orchid Pharma Limited has approved the allotment of 4,45,86,052 equity shares of Rs. 10 each to Dhanuka Laboratories Limited shareholders as part of the amalgamation scheme. The new shares will be listed on NSE and BSE. Post-allotment, the company's paid-up capital is Rs. 59.88 crore.
The amalgamation and subsequent share allotment will impact the company's capital structure and potentially its market presence, warranting a medium impact.
The allotment of shares as part of an amalgamation scheme is generally viewed positively as it signifies corporate restructuring and potential growth.
Orchid Pharma Limited announced the issuance and allotment of 4,45,86,052 fully paid-up equity shares of Rs. 10 each to the eligible shareholders of Dhanuka Laboratories Limited. This allotment is pursuant to the scheme of Amalgamation and became effective from July 10, 2026. The record date for this allotment was July 23, 2026.
The newly allotted shares are proposed to be listed and traded on BSE Limited and the National Stock Exchange of India Limited, and they will rank pari-passu with the existing equity shares of Orchid Pharma.
Following this allotment and the cancellation of cross-holding of Dhanuka Laboratories Limited, the paid-up share capital of Orchid Pharma has increased to Rs. 59,88,52,000 (Rupees fifty-nine crore eighty-eight lakh fifty-two thousand only). This capital is divided into 5,98,85,200 shares of Rs. 10 each.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.